Muenchhoff, Julia
Poljak, Anne
Thalamuthu, Anbupalam
Gupta, Veer B.
Chatterjee, Pratishtha
Raftery, Mark
Masters, Colin L.
Morris, John C.
Bateman, Randall J.
Fagan, Anne M.
Martins, Ralph N.
Sachdev, Perminder S.
Article History
Received: 22 September 2015
Accepted: 10 June 2016
First Online: 6 July 2016
Competing interests
: Dr. Bateman received research grants from Pharma Consortium (Biogen Idec, Elan Pharmaceuticals Inc., Eli Lilly and Co., Hoffman La-Roche Inc., Genentech Inc., Janssen Alzheimer Immunotherapy, Mithridion Inc., Novartis Pharma AG, Pfizer Biotherapeutics R and D, Sanofi-Aventi, Eisai) and is co-founder and part-owner of C2N. There are no conflicts relevant to this manuscript. Dr. Fagan is a member of the scientific advisory boards of IBL International and Roche and is a consultant for AbbVie, Novartis and DiamiR. There are no conflicts relevant to this manuscript. The other authors declare no potential conflict of interest.